Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Neumann

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Hemasphere|April 20, 2026
IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALLNadine Wolgast, Thomas Beder, Mayukh Mondal, et al.
BMC Genomic Data|April 19, 2022
An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapseLorenz Bartsch, Michael P Schroeder, Sonja Hänzelmann, et al.
The Lancet Regional Health. Europe|October 29, 2025
Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysisDavid Baden, Nadine Wolgast, Philipp M Altrock, et al.
Leukemia|March 23, 2024
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemiaThomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, et al.
Blood|April 23, 2013
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutationsMartin Neumann, Sandra Heesch, Cornelia Schlee, et al.
Annals of Hematology|February 11, 2026
Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trialLars Fransecky, Walter Fiedler, Christoph Röllig, et al.
Leukemia|November 21, 2022
Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)Sophie Steinhäuser, Patricia Silva, Lennart Lenk, et al.
Plos One|January 30, 2013
FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitorsMartin Neumann, Ebru Coskun, Lars Fransecky, et al.
Blood Cancer Journal|January 6, 2026
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemiaSophie Steinhäuser, Thomas Beder, Emely Hübner, et al.
Blood Advances|October 5, 2021
Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradationJuan Lázaro-Navarro, Helia Judith Pimentel-Gutiérrez, Anton Gauert, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Hemasphere|April 20, 2026
IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALLNadine Wolgast, Thomas Beder, Mayukh Mondal, et al.
BMC Genomic Data|April 19, 2022
An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapseLorenz Bartsch, Michael P Schroeder, Sonja Hänzelmann, et al.
The Lancet Regional Health. Europe|October 29, 2025
Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysisDavid Baden, Nadine Wolgast, Philipp M Altrock, et al.
Leukemia|March 23, 2024
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemiaThomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, et al.
Blood|April 23, 2013
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutationsMartin Neumann, Sandra Heesch, Cornelia Schlee, et al.
Annals of Hematology|February 11, 2026
Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trialLars Fransecky, Walter Fiedler, Christoph Röllig, et al.
Leukemia|November 21, 2022
Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)Sophie Steinhäuser, Patricia Silva, Lennart Lenk, et al.
Plos One|January 30, 2013
FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitorsMartin Neumann, Ebru Coskun, Lars Fransecky, et al.
Blood Cancer Journal|January 6, 2026
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemiaSophie Steinhäuser, Thomas Beder, Emely Hübner, et al.
Blood Advances|October 5, 2021
Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradationJuan Lázaro-Navarro, Helia Judith Pimentel-Gutiérrez, Anton Gauert, et al.
Pageof 9